Eli Lilly and Company Limited

Lilly House, Priestley Road, Basingstoke, Hampshire, RG24 9NL
Telephone: +44 (0)1256 315 000
Fax: +44 (0)1256 775 858
WWW: http://www.lilly.co.uk
Medical Information e-mail: ukmedinfo@lilly.com
Medical Information Fax: +44 (0)1256 775 569

Patient Information Leaflet last updated on the eMC: 02/12/2011
PIL Zyprexa powder for solution for injection

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 02/12/2011 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
  • Change to information about pregnancy or lactation
Updated on 03/11/2011 and displayed until 02/12/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
  • Change to information about pregnancy or lactation
Updated on 25/03/2011 and displayed until 03/11/2011
Reasons for adding or updating:
  • Change to Further Information section
  • Change to date of revision
  • Change to warnings or special precautions for use
Updated on 03/02/2011 and displayed until 25/03/2011
Reasons for adding or updating:
  • Change to Further Information section
  • Change to date of revision
  • Introduction of new pack/pack size
Updated on 16/11/2010 and displayed until 03/02/2011
Reasons for adding or updating:
  • Change to Further Information section
  • Change to date of revision
  • Change to manufacturer contact details
Updated on 18/01/2010 and displayed until 16/11/2010
Reasons for adding or updating:
  • Change to Further Information section
  • Change to date of revision
  • Change to side-effects
Updated on 13/06/2008 and displayed until 18/01/2010
Reasons for adding or updating:
  • Change to side-effects
  • Change to date of revision
  • Change to warnings or special precautions for use
Updated on 16/05/2008 and displayed until 13/06/2008
Reasons for adding or updating:
  • Transfer to upgraded management system
Updated on 04/02/2008 and displayed until 16/05/2008
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision
Updated on 25/09/2007 and displayed until 04/02/2008
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision
Updated on 01/11/2006 and displayed until 25/09/2007
Reasons for adding or updating:
  • Change to side-effects
  • Change to date of revision
Updated on 10/07/2006 and displayed until 01/11/2006
Reasons for adding or updating:
  • Change to side-effects
  • Change to date of revision
Updated on 28/04/2005 and displayed until 10/07/2006
Reasons for adding or updating:
  • Change to drug interactions
  • Change to date of revision
Updated on 18/02/2005 and displayed until 28/04/2005
Reasons for adding or updating:
  • Change to side-effects
Updated on 15/03/2004 and displayed until 18/02/2005
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 09/01/2004 and displayed until 15/03/2004
Reasons for adding or updating:
  • New PIL for eMC ie a PIL for an existing product but new to the eMC

Active Ingredients/Generics

 
   olanzapine